12:00 AM
Jun 30, 2008
 |  BC Week In Review  |  Company News  |  Deals

Axentis, BioDevelops deal

Axentis acquired BioDevelops Pharma for an undisclosed amount. The acquisition gave Axentis exclusive rights to IP covering the use of molecules for the enzymatic removal of ubiquitin markers from incorrectly folded proteins. The company plans...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >